Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Low Eosinophil Patients Have 39% Reduction, Supporting Broad Label

 
• By Mandy Jackson
  
Shortness of breath
Tezepelumab cut asthma exacerbations on top of standard-of-care drugs • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Respiratory

More from Therapy Areas